Isavuconazole: Difference between revisions
From IDWiki
No edit summary |
(updated aspergillus to EUCAST 2020) |
||
| Line 14: | Line 14: | ||
! rowspan="2" |Species |
! rowspan="2" |Species |
||
! rowspan="2" |ECOFF (mg/L) |
! rowspan="2" |ECOFF (mg/L) |
||
! colspan=" |
! colspan="3" |Breakpoints (μg/mL) |
||
! colspan="4" |Breakpoints (mm) |
|||
|- |
|- |
||
! S |
! S |
||
! |
!ATU |
||
!SDD |
|||
!R |
|||
!S |
|||
! I |
|||
!SDD |
|||
!R |
!R |
||
|- |
|- |
||
|[[Candida albicans]] |
|[[Candida albicans]] |
||
| ⚫ | |||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 38: | Line 27: | ||
|- |
|- |
||
|[[Candida glabrata]] |
|[[Candida glabrata]] |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 49: | Line 33: | ||
|- |
|- |
||
|[[Candida krusei]] |
|[[Candida krusei]] |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 60: | Line 39: | ||
|- |
|- |
||
|[[Candida parapsilosis]] |
|[[Candida parapsilosis]] |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 71: | Line 45: | ||
|- |
|- |
||
|[[Candida tropicalis]] |
|[[Candida tropicalis]] |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 82: | Line 51: | ||
|- |
|- |
||
|[[Cryptococcus neoformans]] |
|[[Cryptococcus neoformans]] |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 93: | Line 57: | ||
|- |
|- |
||
|[[Cryptococcus gattii]] |
|[[Cryptococcus gattii]] |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
| |
||
| |
| |
||
| Line 105: | Line 64: | ||
|[[Aspergillus flavus]] |
|[[Aspergillus flavus]] |
||
|2 |
|2 |
||
|≤1 |
|||
| ⚫ | |||
| ⚫ | |||
| colspan="2" rowspan="5" | |
|||
| |
|>2 |
||
| colspan="4" rowspan="5" | |
|||
|- |
|- |
||
|[[Aspergillus fumigatus]] |
|[[Aspergillus fumigatus]] |
||
|2 |
|2 |
||
|≤1 |
|≤1 |
||
| |
|2 |
||
|>2 |
|||
|- |
|- |
||
|[[Aspergillus nidulans]] |
|[[Aspergillus nidulans]] |
||
|0.25 |
|0.25 |
||
|≤0.25 |
|≤0.25 |
||
| ⚫ | |||
|>0.25 |
|>0.25 |
||
|- |
|- |
||
|[[Aspergillus niger]] |
|[[Aspergillus niger]] |
||
|4 |
|4 |
||
|— |
|||
|— |
|— |
||
|— |
|— |
||
| Line 128: | Line 89: | ||
|1 |
|1 |
||
|≤1 |
|≤1 |
||
| |
|— |
||
|>2 |
|||
|} |
|} |
||
==Dosing== |
==Dosing== |
||
Revision as of 13:08, 22 October 2024
Background
Mechanism of Action
- Azole antifungal that inhibits lanosterol 14-α demethylase in the peptidoglycan synthesis pathway
Spectrum of Activity
- Active against Candida, Cryptococcus, Aspergillus including Aspergillus flavus, Aspergillus fumigatus, and Aspergillus niger, and Mucorales
- Indications include Chromoblastomycosis, Cladophialophora, Coccidioides immitis
Breakpoints
| Species | ECOFF (mg/L) | Breakpoints (μg/mL) | ||
|---|---|---|---|---|
| S | ATU | R | ||
| Candida albicans | ||||
| Candida glabrata | ||||
| Candida krusei | ||||
| Candida parapsilosis | ||||
| Candida tropicalis | ||||
| Cryptococcus neoformans | ||||
| Cryptococcus gattii | ||||
| Aspergillus flavus | 2 | ≤1 | 2 | >2 |
| Aspergillus fumigatus | 2 | ≤1 | 2 | >2 |
| Aspergillus nidulans | 0.25 | ≤0.25 | — | >0.25 |
| Aspergillus niger | 4 | — | — | — |
| Aspergillus terreus | 1 | ≤1 | — | >2 |
Dosing
- Isavuconazole 200 mg IV tid for 6 doses followed by 200 mg IV daily
Renal Dosing
- No adjustment needed
Hepatic Dosing
- No adjustment needed
Safety
Adverse Drug Reactions
- Nausea, vomiting, diarrhea
- Elevated liver enzymes
- Generally transient ALT elevation that does not require change in therapy
- May also include severe cholestatic or hepatocellular enzyme rises within the first few months of therapy
- See also LiverTox
- Hypokalemia
Drug-Drug Interactions
- Increases levels of sirolimus and tacrolimus
- Increases levels of cyclosporine
- Contraindicated with carbamazepine
